| Literature DB >> 29128014 |
Shruti Gadre1, Jason Turowski1, Marie Budev2.
Abstract
Lung transplantation (LTx) has evolved to represent the therapy of choice for many patients with end-stage lung diseases. Appropriate candidate selection for LTx is an important determinant of a positive outcome from transplantation. Posttransplantation survival has steadily improved, but long-term survival continues to be a challenge with a median survival of 5.8 years. Similarly, combined heart-lung transplantation and simultaneous liver-lung transplantation has been performed successfully in select patients who are not expected to survive either organ transplant alone. Moreover, LTx has been performed in patients who develop end-stage pulmonary complications following hematopoietic stem cell transplantation.Entities:
Keywords: HSCT-lung transplantation; Heart-lung transplantation; Liver-lung transplantation; Lobar transplantation; Lung transplantation
Mesh:
Year: 2017 PMID: 29128014 DOI: 10.1016/j.ccm.2017.07.004
Source DB: PubMed Journal: Clin Chest Med ISSN: 0272-5231 Impact factor: 2.878